Rose McNulty

New Jersey

Associate Editorial Director at MJH Life Sciences

Managing Editor at American Journal of Managed Care

✏️Muscle & Fitness, M&F Hers, Men's Fitness Instagram: @rose_mcnulty

Articles

"Exceptionally Long" PFS Projected With Daratumumab Quadruplet for Multiple Myeloma: Pieter Sonneveld, MD, PhD

1 week ago | ajmc.com | Pieter Sonneveld |Mary Caffrey |Rose McNulty

The PERSEUS (NCT03710603) and CEPHEUS (NCT03652064) trials both demonstrated improved depth and duration of responses and progression-free survival (PFS) with a quadruplet regimen of daratumumab plus bortezomib (Velcade), lenalidomide (Revlimid), and dexamethasone (VRd) in patients with multiple myeloma.1,2 Although these trials support the use of frontline daratumumab plus VRd in both transplant-eligible and transplant-ineligible patients, the median PFS for patients in these studies is...
Infection Linked With Nearly a Quarter of Deaths in Lower-Risk MDS

2 weeks ago | ajmc.com | Rose McNulty

Infection was the main cause of death among a cohort of patients with lower-risk myelodysplastic syndromes (LR-MDS), accounting for approximately 1 in 4 deaths within a year of diagnosis, according to a study published in Haematologica.1 The authors identified several risk factors for infection and infection-related death and highlighted the importance of monitoring patients with LR-MDS closely for symptoms of infection.
FDA Approves Prademagene Zamikeracel for Recessive Dystrophic Epidermolysis Bullosa

2 weeks ago | ajmc.com | Rose McNulty

The FDA today approved prademagene zamikeracel (Zevaskyn; Abeona Therapeutics) as the first and only autologous cell-based gene therapy for the treatment of wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB), according to a press release from Abeona Therapeutics.
Adding Venetoclax to Decitabine-Cedazuridine Improves Response in MDS Subgroups

2 weeks ago | ajmc.com | Rose McNulty

Patients with higher-risk myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML) experienced more robust responses to oral decitabine plus cedazuridine when venetoclax was added to the combination, according to a study published in Blood Cancer Journal.1Oral decitabine-cedazuridine (Inqovi; Taiho Oncology) was FDA approved in 2020 for previously treated or untreated primary or secondary MDS.
Symptom Documentation Differences in Acute Cancer Care Suggest Sociodemographic Disparities

3 weeks ago | ajmc.com | Rose McNulty

Unplanned acute care is common among patients with cancer, but there are differences in symptom documentation across racial, sex, and socioeconomic subgroups, according to a study published in JAMA Network Open. The findings highlight possible disparities and suggest a need for interventions that would promote equity and improve symptom management for patients with cancer.
Unhealthy Sleep Patterns, Duration Linked With Obesity

3 weeks ago | ajmc.com | Rose McNulty

Unhealthy sleep patterns and shorter sleep duration both correlated with obesity occurrence in American adults, suggesting that interventions to promote healthy sleep habits could help reduce the risk of obesity, according to a study published in BMC Public Health.1 Obesity, which is considered a major public health issue, has more than doubled since 1990 and affected 890 million people globally in 2022.2 The authors of the current study noted that increasing evidence suggests a link between...
Consensus Guidelines Aim to Optimize DMD Gene Therapy Delivery

3 weeks ago | ajmc.com | Rose McNulty

Multidisciplinary coordination is of the utmost importance to ensure appropriate gene therapy administration, and consensus recommendations presented at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference aimed to provide practical guidelines to supplement existing frameworks for gene therapy treatment in Duchenne muscular dystrophy (DMD).1 Gene therapies have changed the treatment landscape for inherited neurological conditions in recent years, with FDA approvals...
At-Home DMD Video Assessment Found Valid, Reliable

3 weeks ago | ajmc.com | Rose McNulty

A home-based video assessment tool, the Duchenne Video Assessment (DVA) 2.0, is a reliable, valid measure of ease of movement for patients with Duchenne muscular dystrophy (DMD), according to a poster presented at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference.1 The assessment, which utilizes a secure mobile app, may allow for the evaluation of typical performance in the home setting instead of best performance in the clinical setting, according to the study...
Elinzanetant Reduces Vasomotor Symptoms of Menopause Across BMI, Smoking Status

3 weeks ago | patientcareonline.com | Rose McNulty

Elinzanetant significantly reduced vasomotor symptoms (VMS), also known as hot flashes, associated with menopause overall and across a range of body mass index (BMI) and smoking history subgroups, according to pooled data from the phase 3 OASIS-1 (NCT05042362) and OASIS-2 (NCT05099159) clinical trials.1,2 Researchers, led by JoAnn V Pinkerton, MD, professor of obstetrics and gynecology at the University of Virginia, Charlottesville, VA, wrote in the study abstract that understanding the...
Elinzanetant Effective for Menopause Symptoms Across BMI, Smoking Status

4 weeks ago | ajmc.com | Rose McNulty

Elinzanetant significantly reduced vasomotor symptoms (VMS), also known as hot flashes, associated with menopause overall and across a range of body mass index (BMI) and smoking history subgroups, according to pooled data from the phase 3 OASIS-1 (NCT05042362) and OASIS-2 (NCT05099159) trials.1,2 The findings were presented at the 2025 Academy of Managed Care Pharmacy Annual Meeting.